Patents by Inventor Alexandre Kerkis

Alexandre Kerkis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS COMPRISING STEM CELLS EXPRESSING MESENCHYMAL AND NEURONAL MARKERS AND USES THEREOF TO TREAT NEUROLOGICAL DISEASE
    Publication number: 20220193141
    Abstract: The present disclosure relates to a cryopreserved pharmaceutical composition comprising immature dental pulp stem cells (IDPSCs) expressing SOX-1 and SOX-2 and methods of treating a neurological disease or condition comprising systemically administering to a subject a cryopreserved pharmaceutical composition comprising IDPSCs expressing SOX-1 and SOX-2.
    Type: Application
    Filed: December 27, 2021
    Publication date: June 23, 2022
    Inventors: Irina Kerkis, Alexandre Kerkis
  • Compositions comprising stem cells expressing mesenchymal and neuronal markers and uses thereof to treat neurological disease
    Patent number: 11207352
    Abstract: The invention provides pharmaceutical compositions comprising human immature dental pulp stem cells (hIDPSCs) wherein the hIDPSCs express CD44 and CD13. The invention also provides methods of treating a neurological disease or condition comprising systemically administering to a subject a pharmaceutical composition comprising hIDPSCs wherein the hIDPSCs express CD44 and CD13. For example, for treating neurological diseases or conditions including supporting the neuro-protective mechanism in subjects diagnosed with early HD or repairing lost DA neurons in subjects diagnosed with PD.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: December 28, 2021
    Assignees: AVITA INTERNATIONAL LTD., FUNDAÇÃO BUTANTAN
    Inventors: Irina Kerkis, Alexandre Kerkis
  • Multipotent and immunocompatible stem cell concentrate
    Patent number: 11020436
    Abstract: The present invention generally relates to a stem cell concentrate isolated from a mammalian vascularized adipose tissue, biopharmaceuticals containing such concentrate and use thereof in therapies for treating diseases in mammals.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: June 1, 2021
    Assignee: REGENERA—MEDICINA VETERINÁRIA AVANÇADA LTDA.
    Inventors: Alexandre Kerkis, Cristiane Valverde Wenceslau, Michele Andrade De Barros, João Flávio Panattoni Martins
  • MULTIPOTENT AND IMMUNOCOMPATIBLE STEM CELL CONCENTRATE
    Publication number: 20160324899
    Abstract: The present invention generally relates to a stem cell concentrate isolated from a mammalian vascularized adipose tissue, biopharmaceuticals containing such concentrate and use thereof in therapies for treating diseases in mammals.
    Type: Application
    Filed: December 22, 2014
    Publication date: November 10, 2016
    Inventors: Alexandre KERKIS, Cristiane Valverde WENCESLAU, Michele Andrade De BARROS, João Flávio Panattoni MARTINS
  • COMPOSITIONS COMPRISING STEM CELLS EXPRESSING MESENCHYMAL AND NEURONAL MARKERS AND USES THEREOF TO TREAT NEUROLOGICAL DISEASE
    Publication number: 20160184366
    Abstract: The invention provides pharmaceutical compositions comprising human immature dental pulp stem cells (hIDPSCs) wherein the hIDPSCs express CD44 and CD13. The invention also provides methods of treating a neurological disease or condition comprising systemically administering to a subject a pharmaceutical composition comprising hIDPSCs wherein the hIDPSCs express CD44 and CD13. For example, for treating neurological diseases or conditions including supporting the neuro-protective mechanism in subjects diagnosed with early HD or repairing lost DA neurons in subjects diagnosed with PD.
    Type: Application
    Filed: March 9, 2016
    Publication date: June 30, 2016
    Inventors: Irina Kerkis, Alexandre Kerkis
  • PROCESS FOR PRODUCING MULTIPOTENT STEM CELLS AND PROGENITORS
    Publication number: 20160186132
    Abstract: The present invention relates to a non-enzymatic process for producing multipotent stem cells and progenitors from the cultivation of stem cell niches.
    Type: Application
    Filed: August 19, 2014
    Publication date: June 30, 2016
    Applicant: CCB- CENTRO DE CRIOGENIA BRASIL LTDA.
    Inventors: Carlos Alexandre AYOUB, Alexandre KERKIS, Foresto LIZIER
  • Methods, kits and compositions comprising crotamine
    Patent number: 8278265
    Abstract: The present invention refers to uses of crotamine and compositions containing it, based on its characteristic of interaction with genetic material. Under submicromolar quantities, the polypeptide is no longer toxic, presenting the characteristics properties of cell penetration, transport of molecules to the surface, cytoplasm or cell nucleus and particularly, selective cell penetration. The invention also refers to compositions comprising a pharmaceutically effective concentration of crotamine and its use for the treatment of diseases and dysfunctions, based on its characteristics of interaction with genetic material, such as DNA and RNA, and cell selectivity.
    Type: Grant
    Filed: September 18, 2007
    Date of Patent: October 2, 2012
    Assignee: Fundacao de Amparo a Pesquisa do Estado de Sao Paulo—FAPESP
    Inventors: Tetsuo Yamane, Irina Kerkis, Alexandre Kerkis, Gandhi Rádis Baptista, Mirian Akemi Furuie Hayashi, Katsuhiro Konno, Alvaro Rossan B. P. Da Silva, Lygia da Veiga Pereira, Eduardo Brandt De Oliveira
  • Methods, kits and compositions comprising crotamine
    Publication number: 20080181849
    Abstract: The present invention refers to uses of crotamine and compositions containing it, based on its characteristic of interaction with genetic material. Under submicromolar quantities, the polypeptide is no longer toxic, presenting the characteristics properties of cell penetration, transport of molecules to the surface, cytoplasm or cell nucleus and particularly, selective cell penetration. The invention also refers to compositions comprising a pharmaceutically effective concentration of crotamine and its use for the treatment of diseases and dysfunctions, based on its characteristics of interaction with genetic material, such as DNA and RNA, and cell selectivity.
    Type: Application
    Filed: September 18, 2007
    Publication date: July 31, 2008
    Inventors: Tetsuo Yamane, Irina Kerkis, Alexandre Kerkis, Gandhi Radis Baptista, Mirian Akemi Furuie Hayashi, Katsuhiro Konno, Alvaro Rossan B.P. Da Silva, Lygia da Veiga Pereira, Eduardo Brandt De Oliveira